AUTHORS
Amer M. Zeidan, MD, Cynthia Wetmore, MD, PhD2, Jianjun Liu3, Andrew Grigston4, Mairead Carney5, Carrie Brownstein, MD6, Moshe Mittelman, MD7
AFFILIATIONS
1 Yale University, New Haven, Connecticut, United States
2 SSI Strategy/Kyntra Bio, San Diego, California, United States
3 Kyntra Bio, San Diego, California, United States
4 Kyntra Bio, San Diego, California, United States
5 Kyntra Bio, San Diego, California, United States
6 SSI Strategy/Kyntra Bio, San Diego, California, United States
7 Tel Aviv University, Tel Aviv, Israel
ABSTRACT
Background and Significance
Patients with lower-risk myelodysplastic syndrome (MDS) and high red blood cell transfusion burden (HTB) face substantial morbidity. Currently available therapies remain limited to clinic-based parenteral administration and benefit only 35-50% of patients, leaving a considerable unmet need for effective, convenient oral treatment options.
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stimulates coordinated erythropoiesis and improves iron mobilization. It is approved in more than 40 countries for anemia in chronic kidney disease. The prior Phase 3 MATTERHORN MDS study enrolled a high number of patients with low transfusion burden, contributing to a high rate of 8-week RBC transfusion independence (RBC-TI) of 33% in the placebo cohort. Although the response rate was higher with roxadustat than placebo (48% vs. 33%), the difference was not statistically significant. A post-hoc analysis of the HTB subgroup showed a nominally significant higher RBC-TI with roxadustat versus placebo at 8-weeks (36% vs 7%), and a meaningful trend of 12-week (27% vs. 7%) and 16-week RBC-TI (14% vs. 0%), providing the rationale for a dedicated trial in this population.
Study Design and Methods
FGCL-4592-115 is a global phase 3, randomized, double-blind, placebo-controlled multicenter study (NCT NCT07722988). Two-hundred one adult participants with LR-MDS with anemia and HTB will be randomized 2:1 (roxadustat:placebo), stratified by RBC transfusion burden, ring sideroblast status and IPSS-R risk category. A planned interim analysis, allowing for conditional power-based sample size re-estimation, will occur after 102 patients are enrolled and have completed 24 weeks of treatment. Efficacy will be assessed by stratified Cochran-Mantel-Haenszel testing at 1-sided alpha=0.025. The planned sample size will have at least 90% power to detect a difference in response rate in the experimental arm (roxadustat) compared to the control arm (placebo) in 8-week RBC-TI in the first 24 weeks.
Population
Adults 18 years old with IPSS-R very low, low, or intermediate risk MDS HTB.
Key inclusion criteria:
Confirmed MDS with < 5% bone marrow blasts
IPSS-R very low, low, or intermediate risk
High transfusion burden per IWG2018 (>4 and <10 RBC units in each of 2 consecutive 8-week periods prior to randomization)
Hemoglobin less than 10 g/dL
Serum EPO less than 500 IU/L
Refractory to, intolerant of, or ineligible for ESA therapy
May have had prior TGFb directed therapy
Key exclusion criteria:
MDS with del(5q) or secondary MDS
Prior stem cell transplant
Prior therapy with lenalidomide, imetelstat or hypomethylating agents
Unresolved thrombophilia or recent major cardiovascular/thromboembolic events
NYHA Class III/IV heart failure
Treatment
Roxadustat oral tablets 3 times weekly based upon weight band dosing with up titration as per predefined criteria.
Endpoints
Primary: Proportion of participants achieving >8 weeks of RBC transfusion independence (RBC-TI) during weeks 1-24.
Key secondary: >12-week, >16-week and >24-week RBC-TI during weeks 1-48; minor hematologic improvement-erythroid (HI-E) response per IWG 2018 criteria through week 48.
Exploratory: Patient reported outcomes including QLQ-C30, FACIT‑Fatigue and healthcare resource utilization.
Study Duration
The study comprises a 16-week pre-screening observation (prospective or retrospective) to document baseline transfusion burden for eligibility and randomization, an up to 35-day screening period, a 48-week double-blind treatment period, and an optional extension of the double-blind treatment period for those participants deriving clinical benefit. Enrollment of the first participants is expected early in 2027. Participants are in long-term follow-up for up to 3 years.
Key Features and Oversight
This study is focused on LR-MDS with HTB population, which is supported by post hoc analysis of the MATTERHORN study in which the HTB subgroup demonstrated differential clinically meaningful benefit. The study advances a novel oral agent based on a first-in-class mechanism of action (HIF-PH inhibition), offering at-home dosing as an alternative to clinic-based parenteral therapies. This patient-centric, scientifically rigorous design aims to address a well-defined unmet need with a convenient, orally administered therapeutic option. Global, multicenter execution ensures broad, representative enrollment across diverse regions.
DISCLOSURES
Amer M. Zeidan, MD: AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony); AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony)